Hypertrichosis-Acromegaloid Facial Appearance Syndrome Overview
Learn About Hypertrichosis-Acromegaloid Facial Appearance Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Murray Gordon is an Endocrinologist in Pittsburgh, Pennsylvania. Dr. Gordon is rated as an Elite provider by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. His top areas of expertise are Acromegaly, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaloid Facial Appearance Syndrome, Hormone Replacement Therapy (HRT), and Thyroidectomy.
University Professional Services
Maria Fleseriu is an Endocrinologist in Portland, Oregon. Dr. Fleseriu is rated as an Elite provider by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. Her top areas of expertise are Acromegaly, Cushing's disease, Cushing's syndrome, Acromegaloid Facial Appearance Syndrome, and Hormone Replacement Therapy (HRT).
Andrea Giustina practices in Milan, Italy. Ms. Giustina is rated as an Elite expert by MediFind in the treatment of Hypertrichosis-Acromegaloid Facial Appearance Syndrome. Her top areas of expertise are Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Acromegaly, Hormone Replacement Therapy (HRT), and Thyroidectomy.
Summary: There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present...
Summary: The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.